Top FDA Official Appointed By Trump Admin Departs After Three Months
Newsweek6 days
Prasad's departure represents a victory against regulatory overreach that threatened patient access to life-saving treatments. His decision to halt Elevidys shipments ignored desperate families fighting Duchenne muscular dystrophy and demonstrated dangerous government interference in medical decisions. The Wall Street Journal correctly identified this as regulatory "mugging" that chills pharmaceutical innovation.
Prasad's resignation shows how pharmaceutical lobbying and political pressure can undermine legitimate safety concerns at the FDA. His evidence-based approach to drug approvals and willingness to question treatments with questionable efficacy represented exactly the kind of scientific rigor the agency needs. The coordinated attack against him prioritized industry profits over patient safety.
Prasad had to go because any official who prioritizes political ideology over patient access must be held accountable. His decision to halt a life-saving gene therapy for dying children showed callous disregard for families desperate for treatments. This regulatory overreach worked toward destroying President Trump's pro-patient agenda and Right to Try principles.
Prasad had to go because any official who prioritizes political ideology over patient access must be held accountable. His decision to halt a life-saving gene therapy for dying children showed callous disregard for families desperate for treatments. This regulatory overreach worked toward destroying President Trump's pro-patient agenda and Right to Try principles.
Prasad's resignation exposes dangerous political interference in scientific decision-making at the FDA. Although he aligns with right-wing skepticism of vaccines, Prasad was still forced out after making evidence-based safety decisions about a treatment linked to patient deaths. Industry lobbying and activist pressure seem to be overriding legitimate regulatory concerns about drug safety.